Summary
The steady-state intravenous pharmacokinetics of pirenzepine has been investigated in patients with chronic liver disease and others with combined chronic liver disease and renal sufficiency.
The plasma clearance (CL) of Pirenzepine, steady-state plasma concentration Cmin(ss) and dominant half life t1/2γ were not significantly altered in the chronic liver disease group. In patients with renal and hepatic insufficiency, CL was reduced, t1/2γ was prolonged from 11.1 to 19.4 h and Cmin(ss) was elevated from 36 ng/ml to 66 ng/ml compared to healthy controls. Plasma concentrations remained in the therapeutic range and the dosage regimen was well tolerated.
Adjustment of the dose of pirenzepine need be considered only in cases of severe impairment of both renal and hepatic elimination.
Similar content being viewed by others
References
Carmine AA, Brogden RN (1985) Pirenzepine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 30: 85–126
Krakamp B, Tanswell P, Vogel H, Bozler G (1989) Steady-state pharmacokinetics of pirenzepine in patients with differing degrees of renal function impairment. Eur J Clin Pharmacol 36: 75–78
Hammer R, Bozler G, Zimmer A, Koss FW (1977) Pharmakokinetik und Metabolismus von L-S 519 CL2 (Pirenzepin) beim Menschen. Therapiewoche 27: 1575–1593
Kühn HA, Wernze H (1979) Klinische Hepatologie. Thieme, Stuttgart New York
Tanswell P, Kasper W, Zahn G (1986) Automated monoclonal radioimmunoassays for pirenzepine, a selective muscarinic receptor antagonist, in plasma and urine. J Immunol Methods 93: 247–258
Lauterbach F (1987) Intestinal permeation of nonquarternary amines: A study with telenzepine and pirenzepine int he isolated mucosa of guinea pig jejunum and colon. J Pharmacol Exp Ther 243: 1121–1130
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krakamp, B., Tanswell, P., Leidig, P. et al. Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renaland hepatic insufficiency. Eur J Clin Pharmacol 36, 71–73 (1989). https://doi.org/10.1007/BF00561027
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561027